Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | HEXA | P06865 | 1/20 | 0.30 |
| ▸ | HEXB | P07686 | 1/20 | 0.30 |
| ▸ | CDK4 | P11802 | 2/20 | 0.30 |
| ▸ | CCND1 | P24385 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3784110 | 0.85 | HTR1A (0.43) | HTR1ADRD2HEXAHEXBCDK4 | |
| SCHEMBL3427271 | 0.75 | HTR1A (0.46) | HTR1ADRD2DRD3 | |
| SCHEMBL3778885 | 0.75 | BPTF (0.33) | — | |
| SCHEMBL3778688 | 0.75 | BPTF (0.33) | — | |
| SCHEMBL3429771 | 0.74 | HTR1A (0.38) | HTR1ADRD2 | |
| SCHEMBL3429769 | 0.64 | HTR1A (0.36) | HTR1ADRD2 | |
| SCHEMBL2291274 | 0.64 | HTR1A (0.43) | HTR1ADRD2HEXAHEXBCDK4 | |
| SCHEMBL3408971 | 0.62 | KCNH2 (0.31) | — | |
| SCHEMBL3404272 | 0.62 | HTR1A (0.41) | HTR1ADRD2 | |
| SCHEMBL7352146 | 0.62 | HTR1A (0.70) | HTR1ADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257551-B1 | AZATRICYCLIC ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-10 | — | — | EP | disclosed |
| US-8349828-B2 | Azatricyclic antibiotic compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-01-08 | — | — | US | disclosed |
| US-20100331318-A1 | AZATRICYCLIC ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331318-A1 | AZATRICYCLIC ANTIBIOTIC COMPOUNDS | ZYX, AZI2, NAT1 | HTR1A 1449/4885DRD2 806/4885DRD3 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.